YU14003A - Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof - Google Patents

Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof

Info

Publication number
YU14003A
YU14003A YU14003A YUP14003A YU14003A YU 14003 A YU14003 A YU 14003A YU 14003 A YU14003 A YU 14003A YU P14003 A YUP14003 A YU P14003A YU 14003 A YU14003 A YU 14003A
Authority
YU
Yugoslavia
Prior art keywords
bicyclic heterocycles
production
compounds
methods
medicaments containing
Prior art date
Application number
YU14003A
Other languages
Serbo-Croatian (sh)
Inventor
Frank Himmelsbach
Elke Langkopf
Birgit Jung
Stefan Blech
Flavio Solca
Original Assignee
Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh. & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Publication of YU14003A publication Critical patent/YU14003A/en
Publication of RS52279B publication Critical patent/RS52279B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The invention relates to bicyclic heterocycles of general formula (I), in which Ra to Rc are defined as referred to in Claims Nos. 1 to 7, to their tautomers, their stereoisomers, and to their salts, particularly their physiologically compatible salts with inorganic or organic acids or bases, which have valuable pharmacological properties, in particular, an inhibitive effect on the signal transduction imparted by tyrosine kinases. The invention also relates to the use of said bicyclic heterocycles for treating diseases, especially tumor diseases, disorders of the lung and of the respiratory tract, and to the production thereof.
YU14003A 2000-08-26 2001-08-18 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof RS52279B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10042058A DE10042058A1 (en) 2000-08-26 2000-08-26 Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation

Publications (2)

Publication Number Publication Date
YU14003A true YU14003A (en) 2006-01-16
RS52279B RS52279B (en) 2012-10-31

Family

ID=7653945

Country Status (31)

Country Link
EP (1) EP1315705A1 (en)
JP (1) JP4834282B2 (en)
KR (1) KR100862873B1 (en)
CN (1) CN100404517C (en)
AR (1) AR033562A1 (en)
AU (2) AU8769401A (en)
BG (1) BG107559A (en)
BR (1) BR0113519A (en)
CA (1) CA2417897C (en)
CZ (1) CZ302567B6 (en)
DE (1) DE10042058A1 (en)
EA (1) EA005679B1 (en)
EC (1) ECSP034464A (en)
EE (1) EE05269B1 (en)
HK (1) HK1057557A1 (en)
HR (1) HRP20030138A2 (en)
HU (1) HUP0300819A3 (en)
IL (2) IL154602A0 (en)
ME (1) MEP58708A (en)
MX (1) MXPA03001483A (en)
MY (1) MY126132A (en)
NO (1) NO324866B1 (en)
NZ (1) NZ524668A (en)
PL (1) PL360248A1 (en)
RS (1) RS52279B (en)
SK (1) SK287747B6 (en)
TW (1) TWI294422B (en)
UA (1) UA73004C2 (en)
UY (1) UY26903A1 (en)
WO (1) WO2002018351A1 (en)
ZA (1) ZA200300991B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU90901A (en) 1999-06-21 2004-07-15 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
DE10042059A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
EA200701302A1 (en) * 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4- (N-PHYLENAMINO) QUINAZOLIN / -CHINOLINE AS THYROSINKINASE INHIBITORS
DE10214412A1 (en) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and process for their preparation
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
DE10326186A1 (en) * 2003-06-06 2004-12-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10334226A1 (en) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
SI1667992T1 (en) 2003-09-19 2007-06-30 Astrazeneca Ab Quinazoline derivatives
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10345875A1 (en) * 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods of preparation
DE10350717A1 (en) * 2003-10-30 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
KR20070107151A (en) 2005-02-26 2007-11-06 아스트라제네카 아베 Quinazoline derivatives as tyrosine kinase inhibitors
KR100673775B1 (en) * 2005-04-08 2007-01-24 엘지전자 주식회사 Home bar door of refrigerator
JP2009506990A (en) * 2005-08-22 2009-02-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Bicyclic heterocycles, medicaments containing these compounds, their use and methods for their production
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
WO2007101782A1 (en) * 2006-03-09 2007-09-13 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them
MX2009002710A (en) 2006-09-18 2009-03-25 Boehringer Ingelheim Int Method for treating cancer harboring egfr mutations.
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
ME01461B (en) 2008-02-07 2014-04-20 Boehringer Ingelheim Int Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
EP2313397B1 (en) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy substituted heterocycles, medicine containing these connections, their application and production method
KR20200137052A (en) 2009-01-16 2020-12-08 엑셀리시스, 인코포레이티드 Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
SI2451445T1 (en) 2009-07-06 2019-07-31 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
KR101317809B1 (en) 2011-06-07 2013-10-16 한미약품 주식회사 Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cell and non-metalic salt lubricant
KR20140096571A (en) 2013-01-28 2014-08-06 한미약품 주식회사 Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one
BR112015020787B1 (en) 2013-03-06 2022-12-06 Astrazeneca Ab 4-(SUBSTITUTED-ANILINE)-6-O-(SUBSTITUTED-PIPERIZINE-CARBONYL)QUINAZOLINIC COMPOUNDS, THEIR SALTS, PHARMACEUTICAL COMPOSITION, USE AND COMBINATION
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CA2943011A1 (en) * 2014-04-04 2015-10-08 H. Lundbeck A/S Halogenated quinazolin-thf-amines as pde1 inhibitors
US20170176028A1 (en) 2015-12-18 2017-06-22 Lg Electronics Inc. Air conditioner
MA46852A (en) 2016-11-17 2019-09-25 Univ Texas COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS CARRIER OF EGFR OR HER2 MUTATIONS EXON 20
CN112321814B (en) * 2020-12-30 2021-03-23 广州初曲科技有限公司 Preparation and application of gefitinib idebenone conjugate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
TR199801530T2 (en) * 1996-02-13 1998-11-23 Zeneca Limited Quinazoline derivatives as VEGF inhibitors.
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP4464466B2 (en) * 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド 4-anilinoquinazoline derivatives
PL190489B1 (en) * 1996-04-12 2005-12-30 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19911509A1 (en) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation

Also Published As

Publication number Publication date
NZ524668A (en) 2006-06-30
EA005679B1 (en) 2005-04-28
MY126132A (en) 2006-09-29
TWI294422B (en) 2008-03-11
CA2417897C (en) 2009-03-31
CN1449390A (en) 2003-10-15
MEP58708A (en) 2011-05-10
IL154602A0 (en) 2003-09-17
AU8769401A (en) 2002-03-13
NO20030870D0 (en) 2003-02-25
CA2417897A1 (en) 2003-01-30
NO324866B1 (en) 2007-12-17
AR033562A1 (en) 2003-12-26
HK1057557A1 (en) 2004-04-08
SK287747B6 (en) 2011-08-04
JP4834282B2 (en) 2011-12-14
EE05269B1 (en) 2010-02-15
CN100404517C (en) 2008-07-23
NO20030870L (en) 2003-02-25
ECSP034464A (en) 2003-03-31
HUP0300819A2 (en) 2003-09-29
BG107559A (en) 2003-10-31
EP1315705A1 (en) 2003-06-04
HUP0300819A3 (en) 2008-03-28
PL360248A1 (en) 2004-09-06
JP2004507529A (en) 2004-03-11
IL154602A (en) 2008-07-08
HRP20030138A2 (en) 2005-04-30
MXPA03001483A (en) 2003-06-06
DE10042058A1 (en) 2002-03-07
AU2001287694B2 (en) 2007-09-06
EE200300077A (en) 2004-12-15
BR0113519A (en) 2003-07-01
EA200300219A1 (en) 2003-08-28
UA73004C2 (en) 2005-05-16
RS52279B (en) 2012-10-31
WO2002018351A1 (en) 2002-03-07
ZA200300991B (en) 2004-04-16
UY26903A1 (en) 2002-03-22
KR100862873B1 (en) 2008-10-15
KR20030024914A (en) 2003-03-26
CZ302567B6 (en) 2011-07-13
SK2312003A3 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
YU14003A (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
MXPA03001377A (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof.
YU49603A (en) Quinazoline derivatives, medicaments containing said compounds,their utilization and method for the production thereof
MEP45508A (en) Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
MY123642A (en) Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, and processes for preparing them.
MY127771A (en) Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CA2403152A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CA2417652A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
BG105765A (en) 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
CA2417050A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
TW200730508A (en) Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same
AU688972B2 (en) Pyrimido{5,4-d}pyrimidines, drugs containing these compounds, their use, and process for preparing them
MXPA05008780A (en) Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof.
UA101357C2 (en) Normal;heading 1;heading 2;heading 3;SPIROCYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND METHOD FOR THEIR PRODUCTION
TW200510341A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
MX2009007610A (en) Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof.
WO2007023073A3 (en) Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof
WO2000055162A3 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
YU60501A (en) 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases